Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.19 - $0.37 $556 - $1,083
2,929 Added 16.32%
20,880 $4,000
Q3 2023

Nov 14, 2023

BUY
$0.37 - $1.04 $6,641 - $18,669
17,951 New
17,951 $7,000
Q1 2023

May 15, 2023

BUY
$0.76 - $1.78 $58,686 - $137,449
77,219 New
77,219 $70,000
Q3 2022

Nov 14, 2022

BUY
$1.32 - $58.0 $18,412 - $809,042
13,949 New
13,949 $20,000
Q1 2022

May 16, 2022

SELL
$1.82 - $3.5 $57,761 - $111,079
-31,737 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$1.21 - $2.7 $38,401 - $85,689
31,737 New
31,737 $42,000
Q3 2019

Nov 14, 2019

SELL
$0.8 - $1.18 $8,933 - $13,177
-11,167 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$1.2 - $1.85 $13,400 - $20,658
11,167 New
11,167 $14,000

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $76.8M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.